The search textbox has an autosuggest feature. When you enter three or more characters, a list of up to 10 suggestions will popup under the textbox. Use the arrow keys to move through the suggestions. To select a suggestion, hit the enter key. Using the escape key closes the listbox and puts you back at the textbox. The radio buttons allow you to toggle between having all search items start with or contain the text you entered in the search box.
A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity. Ramucirumab specifically binds to and inhibits VEGFR-2, which may result in an in inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR-2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
|Synonym:||anti-VEGFR-2 fully human monoclonal antibody IMC-1121B|
|Chemical structures:||immunoglobulin G1, anti-(human vascular endothelial growth factor receptor type VEGFR-2 extracellular domain) (human monoclonal IMC-1121B γ-chain), disulfide with human monoclonal IMC-1121B κ-chain, dimer |
immunoglobulin G1, anti-(vascular endothelial growth factor receptor 2 (EC 184.108.40.206 or protein-tyrosine kinase receptor Flk-1 or CD309 antigen) extracellular domain); human monoclonal IMC-1121B γ1 heavy chain (219-214')-disulfide with human monoclonal IMC-1121B κ light chain (225-225'':228-228'')-bisdisulfide dimer